YAP1 and malignant colon neoplasm: Recent research has suggested that upregulation of EGFR by YAP1 has contributed to confer chemoresistance to esophageal cancer cells (Song et al., 2015) , another study suggested that YAP1 confers Colon cancer cells chemoresistance to 5FU chemotherapy (Touil et al., 2014), Therefore, YAP1 may promote CRC progression, high cytoplasmic YAP1 expression is associated with a worse survival in stage III CRC patients who received chemotherapy.